BIOMAT Database Logo BIOMAT Database Logo

Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells. 2016

George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
a Neurosurgical Institute, University of Ioannina , Ioannina , Greece.

Glioblastoma is the most malignant primary brain tumor with a median survival of 15 months. Temozolomide (TMZ) is the standard of care for these patients. Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas. In the present study, we found that combination treatment in glioma cells with TMZ and DFP significantly reduced cell viability, produced cell cycle arrest at G2/M phase, and enhanced apoptosis. TMZ and DFP might be a potent new combination treatment for glioblastoma.

UI MeSH Term Description Entries
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
November 2013, Journal of neuro-oncology,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
June 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells In Vitro by Inhibiting Autophagy.
January 2022, Computational intelligence and neuroscience,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
December 2009, Journal of neuro-oncology,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells.
December 2009, Molecular cancer research : MCR,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells.
March 2015, Journal of neuro-oncology,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
April 2004, Cell death and differentiation,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
May 2009, Molecular cancer research : MCR,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
February 2012, Molecular medicine reports,
George A Alexiou, and Paraskevi Gerogianni, and Evrysthenis Vartholomatos, and Athanasios P Kyritsis
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.
September 2020, Anticancer research,
Copied contents to your clipboard!